Home Portfolio Strategy Team News Contact Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutics Candidate to Treat Alcohol Use Disorder Read Article News 2021 2020 ARCHIVE NOVEMBER 22, 2021 Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutics Candidate to Treat Alcohol Use Disorder NOVEMBER 19, 2021 Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium NOVEMBER 17, 2021 Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001 NOVEMBER 16, 2021 Thimble Point and Pear Therapeutics Announce Additional $50 Million in Committed Capital to Fund Business Plan NOVEMBER 10, 2021 Crinetics Pharmaceuticals Presenting New Data From Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress NOVEMBER 10, 2021 Nouscom to Present Interim Data From Phase 1 Trial Evaluating NOUS-209, an &#8220;Off-The-Shelf&#8221; Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors NOVEMBER 10, 2021 Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List NOVEMBER 10, 2021 Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease NOVEMBER 8, 2021 Akouos Appoints Stacy Price as Chief Technical Officer NOVEMBER 4, 2021 NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study 1 2 3 … 86 NEXT PAGE » © 2021 5AM Venture Management LLC Investor Login Contact Us Terms of Use Privacy Policy